Logo image of ELAB

PMGC HOLDINGS INC (ELAB) Stock Fundamental Analysis

NASDAQ:ELAB - Nasdaq - US73017P1021 - Common Stock

2.11  -0.02 (-0.94%)

Premarket: 2.1 -0.01 (-0.47%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ELAB. ELAB was compared to 37 industry peers in the Personal Care Products industry. While ELAB has a great health rating, there are worries on its profitability. ELAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELAB had negative earnings in the past year.
ELAB had a negative operating cash flow in the past year.
ELAB Yearly Net Income VS EBIT VS OCF VS FCFELAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -48.81%, ELAB is doing worse than 80.56% of the companies in the same industry.
ELAB's Return On Equity of -63.92% is on the low side compared to the rest of the industry. ELAB is outperformed by 72.22% of its industry peers.
Industry RankSector Rank
ROA -48.81%
ROE -63.92%
ROIC N/A
ROA(3y)-98.18%
ROA(5y)N/A
ROE(3y)-148.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELAB Yearly ROA, ROE, ROICELAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

ELAB's Gross Margin of 71.15% is fine compared to the rest of the industry. ELAB outperforms 69.44% of its industry peers.
The Profit Margin and Operating Margin are not available for ELAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELAB Yearly Profit, Operating, Gross MarginsELAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

ELAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELAB has been reduced compared to 1 year ago.
ELAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELAB Yearly Shares OutstandingELAB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M
ELAB Yearly Total Debt VS Total AssetsELAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that ELAB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.81, ELAB is doing worse than 80.56% of the companies in the same industry.
There is no outstanding debt for ELAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACC9.25%
ELAB Yearly LT Debt VS Equity VS FCFELAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 3.86 indicates that ELAB has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.86, ELAB belongs to the best of the industry, outperforming 86.11% of the companies in the same industry.
ELAB has a Quick Ratio of 3.40. This indicates that ELAB is financially healthy and has no problem in meeting its short term obligations.
ELAB's Quick ratio of 3.40 is amongst the best of the industry. ELAB outperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.86
Quick Ratio 3.4
ELAB Yearly Current Assets VS Current LiabilitesELAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

ELAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49543.54%.
ELAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 122.42%.
EPS 1Y (TTM)-49543.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29884.05%
Revenue 1Y (TTM)122.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.9%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELAB Yearly Revenue VS EstimatesELAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 500K 1M 1.5M
ELAB Yearly EPS VS EstimatesELAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELAB Price Earnings VS Forward Price EarningsELAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELAB Per share dataELAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PMGC HOLDINGS INC

NASDAQ:ELAB (1/21/2025, 8:00:02 PM)

Premarket: 2.1 -0.01 (-0.47%)

2.11

-0.02 (-0.94%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners6.38%
Inst Owner Change-0.92%
Ins Owners12.57%
Ins Owner Change0%
Market Cap5.46M
AnalystsN/A
Price TargetN/A
Short Float %12.13%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.23
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-45.18
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0.94
BVpS3.3
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.81%
ROE -63.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.15%
FCFM N/A
ROA(3y)-98.18%
ROA(5y)N/A
ROE(3y)-148.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1357.72%
Cap/Sales 7.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.86
Quick Ratio 3.4
Altman-Z -0.81
F-Score4
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49543.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29884.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)122.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-110.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-180.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-186.59%
OCF growth 3YN/A
OCF growth 5YN/A